Featured News
Rethinking Ocular Drug Development
Improving Translatability in Ocular Drug Development
When preclinical results fail to predict clinical outcomes, it is time to rethink how ocular drug development is designed, interpreted, and translated.
Preclinical development of cell products, gene therapy (viral and non-viral), and biologics involves a multitude of challenges that raise questions about translatability, intraocular inflammation, and optimization of immunosuppressive regimens. At Charles River, we focus on delivering more translatable approaches that meet regulatory expectations while minimizing animal use without compromising scientific integrity.”
Shivakumar Vasanth, PhD
Ocular drug development has long relied on established preclinical models and repeat-dose paradigms to evaluate safety and efficacy. However, many programs encounter a persistent challenge: preclinical results do not always translate into clinical success. This disconnect can delay development timelines, increase costs, and introduce regulatory uncertainty.
This issue goes beyond the models themselves. It reflects how models are applied, interpreted, and aligned with human biology and regulatory expectations. Exaggerated efficacy models, immune-mediated responses, and variability in study outcomes can obscure true drug effects and reduce confidence in decision-making.
The Challenge of Variability in Efficacy Models
Variability in ocular efficacy models remains a major barrier to confident decision-making. Differences in lesion formation, treatment response, and study execution can lead to inconsistent results across studies. This variability makes it harder to demonstrate statistical significance and differentiate true drug effects from background noise.
Recent advances in study design and lesion quantification are helping address these issues. Improving consistency in model development and standardizing endpoints can significantly enhance interpretability. In some cases, optimized approaches have reduced sample size requirements by up to 50% while maintaining strong statistical power. These improvements allow teams to move forward with greater confidence and efficiency.
Immunogenicity and Its Impact on Interpretation
Immune response is one of the most complex challenges in ocular biologic development. In repeat-dose studies, immune activation often escalates over time, complicating interpretation.
This makes it difficult to distinguish between:
- Primary drug-related toxicity
- Secondary effects driven by immune response
- Study design artifacts
In many cases, treatments used to manage inflammation introduce additional variables that further complicate interpretation.
Importantly, immune responses observed in preclinical studies do not always translate directly to humans. This raises critical questions about how these findings should be interpreted within IND-enabling programs and highlights the need for more predictive, clinically relevant approaches.
Why Traditional Study Designs Are Being Reconsidered
Sufficient guidelines do not exist to provide a clear preclinical roadmap to an IND submission, especially for biologics known to cause immune-mediated toxicity in preclinical studies. In addition, acceptable preclinical plans are often determined on a case-by-case basis through regulatory discussion.
The combination of variability and immunogenicity is driving a shift in how studies are designed.
For many teams, the instinct has been to extend studies, increase dosing, or add complexity. However, these approaches often introduce additional noise rather than clarity.
Instead, leading strategies are moving toward:
- Pilot studies to assess tolerability and immune response early
- Reduced repeat dosing to preserve interpretability
- Targeted use of immunomodulation when justified
- Early dialogue with regulators to align on study limitations
This shift reflects a broader realization. More data is not always better data. What matters is whether the data generated is interpretable, relevant, and aligned with the regulatory question being asked.
Redefining What “Translatable” Really Means
Translatability is no longer defined by study complexity alone. Instead, it depends on alignment between model biology and human disease, study design and clinical dosing strategy, and endpoints and regulatory expectations.
When these elements are not aligned, even well-executed studies can fail to provide actionable insight.
From Execution to Strategy
Ocular drug development is evolving from a "run the study" mindset to a strategy-first approach. This means clearly defining the decisions a study must support and designing experiments accordingly. By anticipating variability and proactively addressing immunogenicity, teams can improve data clarity and reduce uncertainty.
Organizations that adopt this approach can shorten timelines, reduce costs, and strengthen regulatory confidence. Ultimately, success in ocular drug development will depend on the ability to generate data that clearly, consistently, and clinically relevantly answer the right questions.
Moving Forward With Greater Confidence
The future of ocular drug development will not be defined by any single model or methodology. It will be defined by how effectively scientific rigor, biological relevance, and regulatory alignment are integrated into a cohesive strategy.
Organizations that challenge assumptions and focus on generating meaningful, interpretable data will be best positioned for success.
Explore how your ocular development program can reduce uncertainty, improve translatability, and strengthen IND readiness.